Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment

HIV Clinical Trial

Official title:

A Multicenter, Open-label, Randomized Study to Assess the Metabolics, Efficacy, and Safety of Once-daily Darunavir Versus Atazanavir in HIV-infected Treatment-naive Adult Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00757783
• Other study ID #: CR015439
• Secondary ID: TMC114HIV4023
• Status: Completed
• Phase: Phase 4
• First received: September 19, 2008
• Last updated: November 30, 2015
• Start date: October 2008
• Est. completion date: July 2012

Study information

• Verified date: November 2015
• Source: Tibotec, Inc
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this research study is to compare changes in triglyceride and other lipids (levels of fats found in the blood) from Baseline (Day 1) to Week 12 for darunavir/ritonavir 800/100 mg once daily versus atazanavir/ritonavir 300/100 mg once daily in combination with a fixed-dose background regimen consisting of emtricitabine [FTC]/tenofovir [TDF] 200/300 mg once daily). This study will also evaluate the safety (adverse events), effectiveness, and tolerability of darunavir/ritonavir and atazanivir/ritonavir over 48 weeks.

Description:

The purpose of this study is to expand our understanding of the metabolic effects of darunavir/ritonavir (DRV/r) in HIV-infected patients. This is a phase 4, multicenter, open-label, randomized (study drug assigned by chance), comparative study designed to compare changes in lipid, glucose, and insulin parameters in HIV-infected, anti-retroviral (ARV) naive patients treated with DRV/r 800/100 mg once daily (QD) versus atazanavir/ritonavir (ATV/r) 300/100 mg QD in combination with a common background of emtricitabine (FTC)/ tenofovir (TDF) 200/300 mg QD. In addition, changes in inflammatory markers will be measured. A substudy of the parent study TMC114HIV4023 will evaluate insulin sensitivity and endothelial function in a subset of patients. The study will be conducted at approximately 16 study sites in the United States. Approximately 60 HIV-1 infected, treatment-naive adult patients will be enrolled in the study. Screening will take place during a 4-week period. At the baseline visit, eligible patients will be randomized in a 1:1 ratio to receive DRV/r 800/100 mg QD or ATV/r 300/100 mg QD administered in combination with a fixed-dose background regimen consisting of emtricitabine (FTC)/tenofovir (TDF) 200/300 mg once daily. The treatment period is 48 weeks. Study assessments will be performed at clinic visits at the end of weeks 4, 8, 12, 24, 36, and 48. The primary endpoint will be assessed at week 12. All patients will return for follow up visits 1 week and 4 weeks after the completion of study treatment. During the treatment period, the patient will be seen at regular visits during which the investigator will assess the patient's medical condition, any Adverse Events and study drug compliance. Laboratory evaluations for efficacy and safety will be done at regular visits as well as blood pressure monitoring. Up to twenty patients (evenly randomized to receive DRV/r or ATV/r) who meet additional entry criteria will be enrolled in the substudy. The study hypothesis is the change in triglycerides and other lipids from baseline to week 12 will be similar in the DRV/r arm versus the ATV/r arm. The substudy hypothesis is that DRV/r will not adversely affect insulin sensitivity or endothelial function during 12 weeks of therapy, and the change from baseline in insulin sensitivity and endothelial function will be similar in the DRV/r arm versus the ATV/r arm. During the treatment period, the patient will be seen at regular visits during which the investigator will assess the patient's medical condition, any Adverse Events and study drug compliance. Laboratory evaluations for efficacy and safety will be done at regular visits as well as blood pressure monitoring. Patients will be randomized in a 1:1 ratio to receive darunavir/ritonavir 800/100 mg once daily (QD) plus emtricitabine (FTC)/tenofovir (TDF) 200/300 mg QD or atazanavir/ritonavir 300/100 mg QD plus emtricitabine (FTC)/tenofovir (TDF) for 48 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 68
• Est. completion date: July 2012
• Est. primary completion date: August 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• HIV-1 RNA of 1000 copies/mL or more

• No previous treatment with antiretroviral drugs for more than 10 days

• Demonstrated sensitivity [Fold Change (FC) = lower Clinical Cut Off (CCO)] to tenofovir, darunavir and atazanavir

• Demonstrated sensitivity to emtricitabine defined as absence of M184V/I mutation

• Any CD4 (Cluster of Differentiation 4) cell count

Exclusion Criteria:

• Body mass index >30 kg/m2

• Laboratory parameters as follows: fasting glucose >110 mg/dL, Low-Density Lipoprotein (LDL) cholesterol >130 mg/dL, triglycerides >200 mg/dL

• Presence of any currently active AIDS-defining illness

• Treatment for primary HIV infection or postexposure prophylaxis for HIV

• Patients with acute or chronic hepatitis A, B or C infection

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• HIV

Intervention

Drug:
• ritonavir
100 mg capsule or tablet once daily for 48 weeks
• ritonavir
100 mg capsule or tablet once daily for 48 weeks
• darunavir
800 mg tablet once daily for 48 weeks
• emtricitabine [FTC]/tenofovir [TDF]
200/300 mg tablet once daily for 48 weeks
• emtricitabine [FTC]/tenofovir [TDF]
200/300 mg once daily for 48 weeks
• atazanavir
300 mg capsule once daily for 48 weeks

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Tibotec, Inc	Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Fasting Triglyceride (TG) Levels in the Lipid Evaluable (LE) Set at Week12	Observed values.	Baseline, Week 12	No
Secondary	Change From Baseline in Total Cholesterol (TC) Levels in the LE Set at Week 12 and 48	Observed Values	Baseline, Week 12 and 48	No
Secondary	Change From Baseline in Low Density Lipoprotein (LDL) Direct in the LE Set at Week 12 and 48.	Observed Values	Baseline, Week 12 and 48	No
Secondary	Change From Baseline in High Density Lipoprotein (HDL) in the LE Set at Week 12 and 48.	Observed Values	Baseline, Week 12 and 48	No
Secondary	Change From Baseline in Apolipoprotein A1 in the LE Set at Week 12 and 48.	Observed Values	Baseline, Week 12 and 48	No
Secondary	Change From Baseline in Apolipoprotein B in the LE Set at Week 12 and 48.	Observed Values	Baseline, Week 12 and 48	No
Secondary	Change From Baseline in TC/HDL Ratio in the LE Set at Week 12 and 48.	Participants TC and HDL was analyzed at Baseline and Week 12 and 48. Change from Baseline at Week 12 and 48 was calculated as ratio using observed values.	Baseline, Week 12 and 48	No
Secondary	Change From Baseline in Glucose at Week 12 and 48.	Participants glucose level was analyzed at Baseline and Week 12 and 48. Change from Baseline at Week 12 and 48 was reported.	Baseline, Week 12 and 48	No
Secondary	Change From Baseline in Insulin at Week 12 and 48.	Participants insulin was analyzed at Baseline and Week 12 and 48 and change from Baseline at Week 12 and 48 were reported.	Baseline, Week 12 and 48	No
Secondary	Change From Baseline in Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) at Week 12 and 48.	Participants homeostasis model assessment-insulin resistance (HOMA-IR) were observed and change from Baseline were reported. HOMA-IR score was calculated as: (fasting plasma glucose*fasting serum insulin)/22.5. Low HOMA IR values indicate high insulin sensitivity and high HOMA IR values indicate low insulin sensitivity (insulin resistance).	Baseline, Week 12 and 48	No
Secondary	Antiviral Activity, Human Immunodeficiency Virus Type 1 (HIV-1) RNA.	Number of Participants with antiviral activity, human immunodeficiency virus Type 1 (HIV-1) RNA less than (<) 50 copies per milliliters (copies/mL) or < 400 copies/mL.	Week 12 and 48	No
Secondary	Number of Participants With Antiviral Activity, HIV-1 RNA, Missing Values as Treatment Failure (M=F)	Number of participants with antiviral activity, HIV-1 RNA, missing values as treatment failure (Missing = Failure) were observed.	Week 12 and 48	No
Secondary	Change From Baseline in HIV-1 RNA Viral Load at Week 12 and 48.	the HIV-1 RNA viral load was calculated using Log Base 10 transformed HIV-1 RNA observed values.	Baseline, Week 12 and 48	No
Secondary	Change From Baseline in CD4 Cell Count at Week 12 and 48, Observed Values.	Participants' Cluster of Differentiation (CD) 4 Cell Count were at baseline and the change values at Week 12 and 48 were observed.	Baseline, Week 12 and 48	No
Secondary	Change From Baseline in Cluster of Differentiation (CD) 4 Cell Count at Week 12 and 48, Last Observation Carried Forward (LOCF).	Participants' Cluster of Differentiation (CD) 4 Cell Count were observed at baseline and the change values at Week 12 and 48 was calculated using LOCF.	Baseline, Week 12 and 48	No
Secondary	Change From Baseline in Cluster of Differentiation (CD) 4 Percent at Week 12 and 48, Last Observation Carried Forward (LOCF).	Participants' Cluster of Differentiation (CD) 4 percent were observed at baseline and the change values at Week 12 and 48 was calculated using LOCF.	Baseline, Week 12 and 48	No